Eliana Merle
Stock Analyst at UBS
(0.68)
# 2385
Out of 5,335 analysts
95
Total ratings
28.26%
Success rate
-7.23%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
KYMR Kymera Therapeutics | Maintains: Buy | 72 70 | 31.2 | 124.36% | 3 | May 13, 2025 | |
MRNA Moderna | Maintains: Buy | 78 70 | 25.5 | 174.51% | 7 | May 2, 2025 | |
MDGL Madrigal Pharmaceuti... | Maintains: Strong Buy | 441 458 | 295.59 | 54.94% | 4 | May 2, 2025 | |
CVAC CureVac | Maintains: Buy | 13 12 | 3.4 | 252.94% | 2 | Apr 30, 2025 | |
BBIO BridgeBio Pharma | Maintains: Strong Buy | 65 72 | 33.3 | 116.22% | 3 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 44 | 17.3 | 154.34% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 109 113 | 59.8 | 88.96% | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 25 38 | 7.79 | 387.8% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 42 109 | 40.06 | 172.09% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | 1.22 | 80.33% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 71 | 40.05 | 77.28% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 196 | 161.02 | 21.72% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | 10.02 | 179.44% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 3.21 | 273.83% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 3 | 3.58 | -16.2% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 26 | 5.79 | 349.05% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 33 | 20.53 | 60.74% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 97 131 | 94.76 | 38.24% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 2 | 0.75 | 166.67% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 253 288 | 267.27 | 7.76% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 5 | 4.04 | 23.76% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 18 | 2.9 | 520.69% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 33 | n/a | n/a | 7 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 42 | 12.84 | 227.1% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 40 | n/a | n/a | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 8 | 1.08 | 640.74% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | 4.07 | 440.54% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 8.18 | 474.57% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | n/a | n/a | 1 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 6.04 | 164.9% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 123 | 6.3 | 1852.38% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 192 134 | 26.76 | 400.75% | 3 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 121 | n/a | n/a | 1 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 68 | n/a | n/a | 2 | Oct 22, 2018 |